AIDX · 20/20 Biolabs Inc. Common Stock
View on chartInsiders & Stakes
| John Woodson Rollins Director | ▼ Sell | Other | 30,275 Shares held | 2/19/2026 | View profile |
| John G. Compton Director | ▼ Sell | Other | 14,335 Shares held | 2/19/2026 | View profile |
| Richard M. Cohen Director | ▼ Sell | Other | 7,700 Shares held | 2/19/2026 | View profile |
| Michael A. Ross Director | ▼ Sell | Other | 31 Shares held | 2/19/2026 | View profile |
Transaction History
| Michael A. Ross | ▼ Sell | Other | 31 | $0 | 2/19/2026 |
| John Woodson Rollins | ▼ Sell | Other | 13,029 | $0 | 2/19/2026 |
| John G. Compton | ▼ Sell | Other | 7,669 | $0 | 2/19/2026 |
| Richard M. Cohen | ▼ Sell | Other | 7,700 | $0 | 2/19/2026 |
| John Woodson Rollins | ▼ Sell | Other | 6,135 | $0 | 2/19/2026 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
20/20 BioLabs Sets October Dates for FDA Vote and Investor Updates
20/20 BioLabs has scheduled an investor webinar for October 7, 2026, to discuss an upcoming FDA Advisory Committee vote and its new OneTest franchise model. The company will also take part in the Maxim Growth Summit in New York on October 14, 2026. These events provide key upcoming touchpoints for the stock, which currently trades near its 52-week low.
20/20 BioLabs Sets October Dates for FDA Vote and Investor Updates. 20/20 BioLabs has scheduled an investor webinar for October 7, 2026, to discuss an upcoming FDA Advisory Committee vote and its new OneTest franchise model. The company will also take part in the Maxim Growth Summit in New York on October 14, 2026. These events provide key upcoming touchpoints for the stock, which currently trades near its 52-week low.